Investment Rating - The report does not explicitly state an investment rating for the healthcare IT industry Core Insights - Healthcare IT private equity (PE) deal flow remained strong in H2 2025, with deal counts up 15.9% and deal values up 14.3% compared to the prior year [3] - The largest transaction in H2 2025 was a $2.6 billion leveraged buyout (LBO) of Premier, while the second-largest was a $1.1 billion LBO of AGS Health at an 18.3x 2025 EV/EBITDA multiple [3][9] - The analytics and value-based care segment saw significant growth, with deal count increasing by 109.1% in 2025 [3] - Valuation levels moderated in H2 2025, with EV/EBITDA multiples in the high teens to low 20s, consistent with 2024 levels [3] Summary by Sections Key Takeaways - Healthcare IT PE deal count increased by 2.1% in 2025, with a total transaction value of $43.4 billion, a 23.9% increase from 2024 [5] - Exit activity was strong in 2025, with exit count up 7.7% and exit transaction value up 48%, although it moderated in H2 2025 [5] PE Update - AI-related deals slowed in H2 2025, with a focus on large-scale buyouts rather than pure-play AI investments [8] - The report highlights the transition of CommonSpirit Health to AI-native capabilities, indicating potential shifts in revenue cycle management (RCM) vendor valuations [9] Noteworthy Transactions - The report identifies several significant deals in H2 2025, including the acquisition of UST HealthProof for $1.3 billion and Performant Healthcare for approximately $670 million [16]

Core Insights - Epic has secured a £222 million contract to implement a federated electronic patient record (EPR) system across four NHS Trusts in Somerset and Dorset, aiming to replace legacy systems with a unified solution [5] - The move aligns with the NHS's broader strategy of consolidating digital systems and enhancing interoperability, particularly in rural areas where data sharing has been historically challenging [2][4] Group 1: Contract Details - The contract involves four trusts: Somerset NHS FT, Dorset County Hospital NHS FT, University Hospitals Dorset NHS FT, and Dorset Healthcare University NHS FT, joining 14 other trusts already using Epic's EPR [5] - This contract represents a significant step for Epic, expanding its presence in rural healthcare settings, which contrasts with its previous successes in urban NHS Trusts [5][12] Group 2: Market Dynamics - The NHS EPR market is shifting towards larger, enterprise-wide solutions, driven by ongoing consolidation within the NHS, including the merger of Integrated Care Boards (ICBs) [4] - Epic's EPR is positioned to replace various incumbent systems, including those from System C and SystmOne, contributing to the goal of achieving 100% EPR coverage by the end of 2026 [7][11] Group 3: Competitive Landscape - Epic faces competition from other vendors like Oracle Health, which, along with Epic, covers approximately 45% of the UK population's acute hospital trusts [10] - Concerns have been raised regarding the cost of Epic's solutions, which are influenced by the US market pricing, potentially making them less competitive compared to other vendors offering lower-value contracts [11] Group 4: Future Implications - The deal is expected to enhance interoperability between trusts, as seen in previous successful integrations, such as the collaboration between Great Ormond Street Hospital and Royal Marsden [6] - Smaller vendors may need to focus on differentiation through integration capabilities and support rather than competing directly with large players like Epic and Oracle for large contracts [13]

Core Insights - Blue Door Asset Management increased its position in Waystar by purchasing 322,600 shares valued at approximately $11.49 million based on average pricing for the quarter [1][2] - Waystar reported a revenue of $1.10 billion for 2025, reflecting a 17% year-over-year growth, with adjusted EBITDA reaching around $462 million, a 21% increase year-over-year [10] - Despite a 31.5% decline in stock price over the past year, Waystar's strong growth profile and market position in healthcare technology suggest potential for future capital investment [11][12] Company Overview - Waystar operates in the healthcare technology sector, providing a robust SaaS platform that addresses payment and revenue cycle challenges for healthcare providers [6] - The company serves a diverse customer base, including healthcare providers, hospitals, and health systems across the United States [9] - Waystar's business model focuses on optimizing revenue cycle management through cloud-based software solutions [9] Financial Performance - Waystar's revenue for the fourth quarter climbed 24% to approximately $304 million, indicating continued momentum in the adoption of automation tools by healthcare providers [10] - The company is projecting revenue of about $1.28 billion and adjusted EBITDA of $535 million for the upcoming year, highlighting expected growth [12] Market Position - Waystar's stock price as of the last report was $24.16, significantly underperforming compared to the S&P 500's roughly 20% gain over the same period [8] - The company ranks among the larger holdings in Blue Door's portfolio, indicating a strong conviction in the healthcare software sector [12]

Core Insights - Health Catalyst (HCAT) reported revenue of $74.68 million for the quarter ended December 2025, reflecting a year-over-year decline of 6.2% while EPS increased to $0.08 from $0.04 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $73.61 million, resulting in a surprise of +1.45%, although the EPS fell short of the consensus estimate of $0.09 by -14.26% [1] Revenue Breakdown - Professional services revenue was $22.81 million, slightly below the estimated $22.88 million, marking an 18.6% decline compared to the same quarter last year [4] - Technology revenue reached $51.87 million, surpassing the estimated $50.74 million, with a modest year-over-year increase of 0.5% [4] Profit Metrics - Adjusted Gross Profit for Professional Services was $4.61 million, slightly below the average estimate of $4.68 million [4] - Adjusted Gross Profit for Technology was $35.35 million, exceeding the estimated $34.51 million [4] Stock Performance - Over the past month, shares of Health Catalyst have returned -6.5%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, representing a 1% year-over-year growth [16][17] - In Q4 2025, total revenue was $74.7 million, down from $79.6 million in the prior year period [16][17] - Adjusted gross margin for Q4 was 53.5%, compared to 46.6% in the prior year [18] - Adjusted operating expenses for Q4 were $26.2 million, representing 35% of revenue, down from 37% in Q4 2024 [18][19] - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, leading to a GAAP net loss of $178 million, up from a loss of $69.5 million in 2024 [19][20] Business Line Data and Key Metrics Changes - Technology revenue for Q4 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services attributed to reduced FTE service offerings [17] - For the full year, technology revenue increased by 7% year-over-year to $208.3 million, while professional services revenue declined by 8% [17] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [16] - The dollar-based retention rate for technology plus TAMS closed the year at 93% [16] Company Strategy and Development Direction - The company is focused on long-term success and is conducting a strategic review to position itself better for shareholder value [6][29] - There is a renewed emphasis on simplifying the commercial engine to drive technology ARR bookings and improve retention through predictable migrations [12][13] - The company aims to leverage its intellectual property and expertise in AI to differentiate itself in the market [12] Management's Comments on Operating Environment and Future Outlook - Management noted that the healthcare market is under pressure, with clients needing to manage costs while maintaining clinical quality [40] - The company is not providing full-year guidance for 2026 but expects Q1 revenue to be between $68 million and $70 million, with Adjusted EBITDA of $7 million to $8 million [21][22] - There are anticipated challenges related to the DOS to Ignite migration, with expected revenue declines due to downselling and churn [22][23] Other Important Information - The company is undergoing leadership changes, with a new CEO emphasizing a back-to-basics approach and a focus on core capabilities [6][9] - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [9][12] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, but is currently in an assessment mode [29][31] Question: Can you elaborate on the transition impact regarding the $52 million in data platform revenue? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter facing the highest pressure during the migration [35][66] Question: What insights were gained regarding bookings and demand in Q4? - The market is in need of better cost management and clinical quality, which is reflected in the sales funnel and demand for the company's solutions [40] Question: How does the company plan to maintain client relationships amid potential downsells? - The company generally retains application relationships even when facing downsells in data platform infrastructure, focusing on client needs and expertise [49][66] Question: What is the expected impact of the DOS-related ARR churn on 2026? - Approximately 75% of the $12.5 million in ARR churn is expected to impact 2026, with negotiations ongoing to retain application relationships [65][66]

Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, with total revenue for Q4 2025 at $74.7 million, down from $79.6 million in the prior year period [25][26] - Adjusted gross margin for Q4 2025 was 53.5%, compared to 46.6% in the prior year period, while for the full year, it was 51.1% driven by technology gross margin of 67.4% and professional services gross margin of 18.3% [27] - Adjusted operating expenses for Q4 2025 were $26.2 million, representing 35% of revenue, down from $29.2 million or 37% of revenue in Q4 2024 [28] Business Line Data and Key Metrics Changes - Technology revenue for Q4 2025 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services revenue attributed to reductions in FTE service offerings and exiting unprofitable pilot arrangements [25][26] - For the full year, technology revenue increased 7% year-over-year to $208.3 million, while professional services revenue declined 8% [27] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [25] - The tech plus TAMS dollar-based retention closed the year at 93% [25] Company Strategy and Development Direction - The company is focused on long-term success, emphasizing a back-to-basics approach to deliver measurable outcomes across cost efficiency, clinical improvement, and consumer experience [10][17] - Plans include tightening leadership focus, improving operational rigor, and simplifying the commercial story to better articulate the value proposition [12][16] - The company aims to strengthen and simplify its commercial engine to drive technology ARR bookings and improve retention through predictable migrations [19][21] Management's Comments on Operating Environment and Future Outlook - Management noted that the market is under pressure, with clients needing to manage costs while maintaining clinical quality [56] - The company is currently in an assessment mode to best position itself for shareholder value, with no immediate plans for selling the company [44][46] - The first quarter of 2026 is expected to see revenue of $68 million to $70 million and Adjusted EBITDA of $7 million to $8 million, with anticipated challenges due to migration-related revenue declines [33][35] Other Important Information - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, primarily due to a decrease in market cap and forecast revisions [31] - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [13][22] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, with no definitive answer on selling the company at this time [44][46] Question: Can you elaborate on the transition impact regarding the $52 million in data platform revenue? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter experiencing the highest pressure during the migration [50][51] Question: What insights were gained regarding bookings and demand environment in Q4? - The market is in need of better cost management and clinical quality, with significant pressure on profitability for provider clients [56] Question: How does the company plan to maintain client relationships amid data platform disintermediation? - The company aims to retain application relationships while addressing the challenges posed by data platform infrastructure changes [52][66] Question: What is the expected impact of the $12.5 million in ARR churn on 2026? - Approximately 75% of the $12.5 million is expected to impact 2026, with more details to be provided in future guidance [84][85]

Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, with total revenue for Q4 2025 at $74.7 million, down from $79.6 million in the prior year period [15][16] - Adjusted gross margin for Q4 2025 was 53.5%, compared to 46.6% in the prior year period, while for the full year, it was 51.1% [17] - Adjusted operating expenses for Q4 2025 were $26.2 million, representing 35% of revenue, down from 37% in Q4 2024 [17][18] - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, leading to a GAAP net loss of $178 million, up from a loss of $69.5 million in 2024 [18][19] Business Line Data and Key Metrics Changes - Technology revenue for Q4 2025 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services attributed to reduced FTE service offerings [16] - For the full year, technology revenue increased by 7% year-over-year to $208.3 million, while professional services revenue declined by 8% [16] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [15] - The dollar-based retention rate for technology plus TAMS closed the year at 93% [15] Company Strategy and Development Direction - The company is focused on tightening leadership and execution discipline, with plans to strengthen operational rigor and clarify market positioning [6][7] - A renewed focus on simplifying the commercial engine to drive technology ARR bookings and improve retention through predictable migrations is emphasized [11][12] - The company aims to leverage its intellectual property and expertise in AI to solve pressing healthcare problems [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging market conditions for clients, emphasizing the need for better cost management and clinical quality [43][46] - The company is currently in an assessment mode regarding its strategic positioning and potential opportunities for shareholder value [28][31] - Guidance for Q1 2026 revenue is expected to be between $68 million and $70 million, with Adjusted EBITDA of $7 million to $8 million [20] Other Important Information - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [8][12] - The company is not yet in a position to provide full-year guidance for 2026 but plans to offer more clarity in the next earnings call [14][64] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, but no definitive answer was provided regarding a sale [27][28][31] Question: Can you elaborate on the transition impact and the $52 million in data platform revenue at risk? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter facing the highest pressure during the migration [34][35] Question: What insights were gained regarding bookings and demand in Q4? - The market is under pressure to manage costs and improve clinical quality, which is reflected in the demand for the company's solutions [41][43] Question: How does the company plan to maintain margins amid revenue pressure? - There is expected pressure on gross margins due to migration costs, but these are anticipated to be removed post-migration [61][63] Question: Can you break down the $12.5 million in ARR churn and its impact on 2026? - Approximately 75% of the $12.5 million is expected to impact 2026, with more details to be provided in the upcoming guidance [68][70]

Core Insights - CareCloud resumed dividends on preferred shares in 2025 and plans to pay double dividends on Series B preferred stock starting in 2026 to address arrearages [1] - The company converted approximately 80% of Series A preferred shares into common stock in 2025, eliminating over $7 million in annual dividend obligations [1] Financial Performance - Non-GAAP free cash flow was $20.5 million in 2025, a 55% increase from $13.2 million in 2024, indicating improved financial flexibility [2] - GAAP operating cash flow reached $28.6 million in 2025, up 38% year over year, with $8.7 million generated in Q4, a 66% increase [3] - Adjusted EBITDA for the full year was $27.5 million, representing a 23% margin, and increased 15% from $24.1 million in 2024 [4] - GAAP net income for 2025 was $10.8 million, up over 37% year over year, marking the first full year of positive EPS since the 2014 IPO [6] Revenue Growth - Full-year revenue for 2025 was $120.5 million, up nearly 9% year over year, with Q4 revenue at $34.4 million, a nearly 22% increase from the prior year [7] - CareCloud raised revenue guidance twice in 2025 and exceeded its final target [7] Strategic Acquisitions - CareCloud completed multiple acquisitions in 2025, funded entirely through free cash flow, resulting in no common shareholder dilution [10] - The acquisition of Medsphere Systems expanded CareCloud's reach into the inpatient hospital market and added new software products [11] - The fourth-quarter revenue included approximately $7.2 million related to the Medsphere acquisition [12] AI Initiatives - CareCloud launched an AI Center of Excellence in April 2025, focusing on integrating AI solutions into healthcare workflows [14] - The flagship AI product, stratusAI Desk Agent, was fully released in December 2025, handling various administrative tasks [15] - AI tools are being utilized to improve revenue cycle management operations, aiming for "zero touch claims" with minimal human intervention [17] 2026 Guidance - For 2026, CareCloud guided revenue of $128 million to $130 million and adjusted EBITDA of $29 million to $31 million, reflecting margin expansion [19] - GAAP EPS is expected to be between $0.20 and $0.23, representing an increase of over 100% from 2025 [19] Market Position - CareCloud's healthcare IT solutions are supported by over 25 years of proprietary data, providing a competitive advantage in the industry [21] - The company serves small to mid-size physician groups and specialty clinics across the United States, enhancing operational efficiency through its cloud-based platform [23][24]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $120.5 million, representing nearly 9% year-over-year growth [7] - In Q4 2025, revenue reached $34.4 million, up nearly 22% year-over-year, indicating accelerating momentum [7] - GAAP net income for 2025 was $10.8 million, a year-over-year increase of more than 37%, with earnings per share of $0.10 [7] - Adjusted EBITDA expanded to $27.5 million with a 23% margin, up more than 14% year-over-year [8] - Free cash flow for 2025 reached approximately $20.5 million, compared to $13.2 million in 2024, representing growth of more than 500% from 2023 [8] Business Line Data and Key Metrics Changes - The company completed multiple acquisitions in 2025, including Medsphere Systems, which expanded its capabilities into the inpatient hospital market [10] - The integration of AI tools into the platform has already resulted in new customer wins under the CareCloud umbrella [11] - The company aims to penetrate newly acquired health system customers with its RCM and AI products as part of its 2026 growth strategy [12] Market Data and Key Metrics Changes - The healthcare technology market is at an inflection point, with AI adoption moving from pilot programs to production deployment [12] - The company recognizes a multi-billion-dollar addressable opportunity in the U.S. for its AI front desk assistant [12] Company Strategy and Development Direction - The company’s 2026 growth strategy focuses on leveraging its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies [13] - Strategic acquisitions have been a cornerstone of growth, with a disciplined approach to acquiring companies at attractive valuations [14] - The company plans to remain active in M&A in 2026 and beyond, identifying complementary targets that can benefit from its AI capabilities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $128 million to $130 million for 2026, with adjusted EBITDA of $29 million to $31 million [15] - The company anticipates GAAP EPS of $0.20 to $0.23 per share, representing an increase of more than 100% over 2025 [15] - Management highlighted the importance of disciplined execution, innovation, and creating long-term value for stakeholders [35] Other Important Information - The company resumed dividends on its preferred shares at the beginning of 2025 and plans to pay double dividends on Series B preferred stock starting in 2026 [9] - The conversion of approximately 80% of Series A preferred shares into common eliminated more than $7 million in annual dividend obligations [9] Q&A Session Summary Question: Can you expand on how you're planning on monetizing AI in 2026? - Management discussed the favorable M&A environment and the strategy to integrate AI capabilities into acquired platforms, enhancing their attractiveness and market position [38][41] Question: What was behind the recent contract wins with new customers? - Management noted the expansion of the sales and marketing team and the focus on cross-selling and upselling existing customers, particularly those acquired through recent transactions [45][46] Question: How should investors think about CareCloud's exposure to AI disruption? - Management emphasized that the company operates in a niche healthcare IT space with deep industry moats, making it less vulnerable to generic AI disruptions [54][56] Question: What are the focuses for the use of excess cash flow? - Management indicated that the focus would be on acquisitions, enhancing the capital structure, and investing in AI development [73] Question: Who are the company's main competitors? - Management identified competitors in the EHR space such as eClinicalWorks and athenahealth, and noted that the AI competitive landscape is broader, with some players lacking a vertical approach [75][78]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $120.5 million, representing nearly 9% year-over-year growth [7] - In Q4 2025, revenue reached $34.4 million, up nearly 22% year-over-year, indicating accelerating momentum [7] - GAAP net income for 2025 was $10.8 million, a year-over-year increase of more than 37%, with earnings per share of $0.10 [7] - Adjusted EBITDA expanded to $27.5 million with a 23% margin, up more than 14% year-over-year [8] - Free cash flow reached approximately $20.5 million for 2025, compared to $13.2 million in 2024, representing growth of more than 500% from 2023 [8] Business Line Data and Key Metrics Changes - The company completed multiple acquisitions in 2025, including Medsphere Systems, which expanded its capabilities into the inpatient hospital market [10] - The integration of AI tools into the platform has already resulted in new customer wins under the CareCloud umbrella [11] - The company aims to penetrate newly acquired health system customers with its RCM and AI products as part of its 2026 growth strategy [12] Market Data and Key Metrics Changes - The healthcare technology market is at an inflection point, with AI adoption moving from pilot programs to production deployment [12] - The company recognizes a multi-billion-dollar addressable opportunity in the U.S. for its AI front desk assistant [12] Company Strategy and Development Direction - The company’s 2026 growth strategy focuses on leveraging its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies [13] - Strategic acquisitions have been a cornerstone of growth, with a disciplined approach to acquiring companies at attractive valuations [14] - The company plans to remain active in M&A in 2026 and beyond, identifying complementary targets that can benefit from its AI capabilities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $128 million-$130 million for 2026, with adjusted EBITDA of $29 million-$31 million [15] - The company anticipates GAAP EPS of $0.20-$0.23 per share, representing an increase of more than 100% over 2025 [15] - Management highlighted the importance of disciplined execution and innovation to create long-term value for stakeholders [35] Other Important Information - The company resumed dividends on its preferred shares at the beginning of 2025 and plans to pay double dividends on Series B preferred stock starting in 2026 [9] - The conversion of approximately 80% of Series A preferred shares into common eliminated more than $7 million in annual dividend obligations [9] Q&A Session Summary Question: Can you expand on how you're planning on monetizing AI in 2026? - Management discussed the favorable M&A environment and the strategy to integrate AI capabilities into acquired platforms to enhance their attractiveness and market position [38][41] Question: What was behind the recent contract wins and future opportunities? - Management noted the expansion of the sales team and the focus on cross-selling additional services to existing clients acquired through recent transactions [45][46] Question: How does CareCloud's exposure to AI disruption compare to being an AI beneficiary? - Management emphasized that CareCloud operates in a niche healthcare IT space with deep industry moats, making it less vulnerable to generic AI disruptions [54][56] Question: What are the focuses for the use of excess cash flow? - Management indicated that the focus would be on acquisitions, enhancing capital structure, and investing in AI development [73] Question: Who are CareCloud's main competitors? - Management identified competitors in the EHR space such as eClinicalWorks and athenahealth, and noted that the AI competitive landscape varies depending on the product [75][76]